Trial record 2 of 30 for:    " October 30, 2011":" November 29, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Bioequivalence Study of Pediatric Formulations to Treat HIV Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Elim Pediatric Pharmaceuticals Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Elim Pediatric Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01469520
First received: November 4, 2011
Last updated: November 8, 2011
Last verified: November 2011
  Purpose

The purpose of the study is to determine the bioavailability/bioequivalence of two pediatric formulations (tablet and reconstitutable suspension) of lamivudine/zidovudine/ nevirapine in comparison to an innovator product. Establishing the bioequivalence of a newly developed age-appropriate fixed dose combination of lamivudine/zidovudine/ nevirapine as an oral dispersible tablet or a reconstitutable suspension for children is invaluable for future product registration and availability of the products to children, thus filling the void in pediatric HIV/AIDS therapy.


Condition Intervention Phase
HIV
AIDS
Drug: Epivir®, Retrovir® and Viramune®
Drug: Lamivudine, Zidovudine and nevirapine
Drug: Lamivudine, zidovudine, nevirapine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers

Resource links provided by NLM:


Further study details as provided by Elim Pediatric Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Bioequivalence between the tests and reference drugs [ Time Frame: 90 days ] [ Designated as safety issue: No ]
    The BE criterion established by the Food and Drug administration requires that the 90 % confidence interval of the ratio of suspension or tablet/co-administered liquid mixtures of the individual drugs for all the three parameters (Cmax, AUC0-t, AUC0-∞)should lie within 80 to 125 % range.


Enrollment: 24
Study Start Date: October 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Reference
Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
Drug: Epivir®, Retrovir® and Viramune®
12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
Other Names:
  • Lamivudine
  • Zidovudine
  • Nevirapine
Active Comparator: Test product
Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
Drug: Lamivudine, Zidovudine and nevirapine
20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
Other Names:
  • Lamivudine
  • Zidovudine
  • Nevirapine
Drug: Lamivudine, zidovudine, nevirapine
Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
Other Names:
  • Lamivudine
  • Zidovudine
  • Nevirapine
Active Comparator: Test Product
Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
Drug: Lamivudine, Zidovudine and nevirapine
20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
Other Names:
  • Lamivudine
  • Zidovudine
  • Nevirapine
Drug: Lamivudine, zidovudine, nevirapine
Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
Other Names:
  • Lamivudine
  • Zidovudine
  • Nevirapine

Detailed Description:

Volunteer Selection and Size: The International Conference on Harmonization (ICH) guideline E11 on clinical investigation of medicinal products in the pediatric population suggests that for relative bioavailability comparison of pediatric formulations, adult subjects may be used. Therefore, the study will be performed in a minimum of 24 healthy adult subjects. However, 29 healthy adults will be enrolled to allow for two possible drop-outs and for three subjects that may develop hypersensitivity to nevirapine which is known for its hypersensitivity side effect, in form of rashes.

In anticipation of such reactions,10% more of the 26 subjects will be added to the group. This will make a total of 29 volunteers during the study. Advertisements announcing the study will be posted at the Bowen University Teaching Hospital two months before the commencement of the study to invite volunteers.

Informed Consent Procedure: The volunteers will be screened using a questionnaire (see attached). The language of communication will be English or a local language used by the community. Researchers will explain to the volunteers on an individual basis, the nature of the study, what would be expected of them and their rights. Volunteers may choose to drop out of the study at any time without any restrictions. Volunteers will be informed that the screening procedure also includes physical examination and laboratory test. Following informed consent, using Consent to Participate Form (see attached) and counseling, volunteers may be enrolled for the study.

A baseline laboratory tests for: packed cell volume, white blood cell count with differentiation, platelet estimation, liver function (aspartate aminotransferase [SGOT], alanine aminotransferase [SGPT]), renal function (serum creatinine), blood urea nitrogen (BUN), pregnancy test (females only), HIV/AIDS, and hepatitis B and C tests will be done two weeks prior to dosing. Volunteers may not consume alcohol, tobacco, caffeine containing products, herbal or other drugs during the study.

Eligibility: The inclusion criteria are as follows: Adult males and females found normal on the basis of a pre-trial physical examination, medical history and the results of blood biochemistry and hematology tests; subject is competent and willing to sign informed consent form voluntarily after being given all the detailed information about the study; willingness to be hospitalized for a 24-hour intensive sampling period.

Exclusion criteria:

  • Hypersensitivity to study drugs, alcoholism, anemia, evidence of pregnancy
  • Abnormal laboratory test; smokers;
  • Any clinically significant diseases or findings during the screening medical history or physical examination that, in the opinion of the investigator, may interfere with the study;
  • Treatment with experimental or prescribed drugs within 30 days prior to the beginning of the study

Confidentiality: Volunteer's name as it appears on the questionnaire will be linked to an identification number. All other documents will have only the identification number instead of your name. The name will not be used in any public document. All written materials and consent forms will be stored in a locked file in the researcher's office. All materials will be destroyed by shredding five years after the completion of the research.

  Eligibility

Ages Eligible for Study:   22 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The eligibility criteria included adults between 22 and 55 years;
  • Healthy as determined on the basis of a pre-trial physical examination, medical history, electrocardiogram and the results of blood biochemistry and hematology tests;
  • Subject was competent and willing to sign informed consent form voluntarily after being given all the detailed information about the study;
  • Willing to be hospitalized for the 24-hour intensive sampling period.

Exclusion Criteria:

  • The exclusion criteria was hypersensitivity to study drugs;
  • Abnormal laboratory biochemistry values;
  • Smokers;
  • Any clinically significant diseases or findings during the screening, medical history or physical examination that, in the opinion of the investigator, may interfere with the study;
  • Treatment with experimental drugs within 30 days prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01469520

Locations
Nigeria
Bowen University Teaching Hospital
Ogbomoso, Oyo State, Nigeria, 234
Sponsors and Collaborators
Elim Pediatric Pharmaceuticals Inc.
Investigators
Principal Investigator: Moji C Adeyeye, Ph.D Elim Pediatric Pharmaceuticals Inc. and Roosevelt University
Study Director: Daniel A Gbadero, MD Bowen University Teaching Hospital, Ogbomoso, Nigeria
  More Information

No publications provided

Responsible Party: Elim Pediatric Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT01469520     History of Changes
Other Study ID Numbers: RU 2010-73, 2010-73
Study First Received: November 4, 2011
Last Updated: November 8, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Elim Pediatric Pharmaceuticals Inc.:
HIV
AIDS
Treatment

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Zidovudine
Nevirapine
Lamivudine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on August 20, 2014